2007 ◽  
Vol 36 (1) ◽  
pp. 50-56 ◽  
Author(s):  
EDWARD B. SILVERMAN ◽  
ROBERT W. READ ◽  
CAROLYN R. BOYLE ◽  
ROBERT COOPER ◽  
WILLIAM W. MILLER ◽  
...  

2020 ◽  
Vol 76 (6) ◽  
pp. 247-252
Author(s):  
Štěpán Rusňák ◽  
Lenka Hecová ◽  
Zdeněk Kasl ◽  
Markéta Sobotová ◽  
Lukáš Hauer

In intraocular tumors, diagnosis is usually based on clinical examination and imaging without the need for invasive surgery or tissue sampling. The diagnosis can be confirmed by biopsy, however, in the case of intraocular malignancy, the biopsy is considered controversial. Due to the development of uveal melanoma cytogenetic prognostics and the progression in generalised uveal melanoma treatment, intraocular melanoma biopsy is becoming increasingly important. Diagnostic biopsy of intraocular tumors is indicated in cases of diagnostic uncertainty for findings with conflicting non-invasive test results and for small melanocyte lesions. Tumor prognostic biopsy is performed to obtain a tissue sample for tumor cytogenetic testing, which can help to determine the prognosis and specific metastatic risk of the patient. For anterior segment tumors, anterior chamber fluid sampling, thin-needle iris biopsy, punch biopsy, surgical biopsy or biopsy using vitrectomy may be used. For posterior segment tumors, procedures include transscleral or transretinal thin-needle biopsy, vitrectomy-assisted biopsy, punch biopsy, endoresection or transscleral exoresection. Complications of intraocular melanoma biopsy include too small or non-valuable sample collection, intra-tumoral heterogeneity, intra-ocular trauma and induction of intraocular or extraocular tumor dissemination.


2021 ◽  
Author(s):  
Femi Adeniyi ◽  
Kunle Oyedokun

BACKGROUNDSkin biopsy has limited but sometimes distinctly useful place in diagnosis of childhood rheumatologic disorders. For example, skin biopsy is of little value in differentiating lupus from dermatomyositis. The purpose of skin biopsy is to support diagnosis, disease monitoring (e.g.scleroderma) or treatment (e.g., skin cancer). OBJECTIVETo evaluate skin biopsy practices in a tertiary paediatric rheumatology unit in order to determine the usefulness. METHODA retrospective review of medical records of paediatric rheumatology patients who have had skin biopsy over a 10-year period between 2008 and 2018 at Alder Hey Children Hospital.RESULTS & DISCUSSIONA total of 49 skin biopsies with an average of 5 per year was performed. Patients age range from 0.75 -18 years with mean of 10 years. Sites of biopsy and main diagnoses are as shown in figure 1 & 2. Fifty nine percent had excision biopsy while 41% had punch biopsy. Majority of skin biopsies (94%) were performed to aid diagnosis. Severe HSP was the most common indi?cation for skin biopsies requested by rheumatologist. A high proportion of the biopsies (84%) were helpful in the patient care; 55% confirmed clinical suspicions, 25% excluded. CONCLUSION & PERSPECTIVESRheumatologist are selective in the use of skin biopsy for diagnosis. When indicated, skin biopsy is often helpful in the diagnosis and monitoring of rheumatologic disorders. It must be ensured that sufficient information with clear clinico-pathologic question is provided when requesting skin biopsy to enhance positive result.


2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Anastasia Kuzkina ◽  
Connor Bargar ◽  
Daniela Schmitt ◽  
Jonas Rößle ◽  
Wen Wang ◽  
...  

AbstractSkin α-synuclein deposition is considered a potential biomarker for Parkinson’s disease (PD). Real-time quaking-induced conversion (RT-QuIC) is a novel, ultrasensitive, and efficient seeding assay that enables the detection of minute amounts of α-synuclein aggregates. We aimed to determine the diagnostic accuracy, reliability, and reproducibility of α-synuclein RT-QuIC assay of skin biopsy for diagnosing PD and to explore its correlation with clinical markers of PD in a two-center inter-laboratory comparison study. Patients with clinically diagnosed PD (n = 34), as well as control subjects (n = 30), underwent skin punch biopsy at multiple sites (neck, lower back, thigh, and lower leg). The skin biopsy samples (198 in total) were divided in half to be analyzed by RT-QuIC assay in two independent laboratories. The α-synuclein RT-QuIC assay of multiple skin biopsies supported the clinical diagnosis of PD with a diagnostic accuracy of 88.9% and showed a high degree of inter-rater agreement between the two laboratories (92.2%). Higher α-synuclein seeding activity in RT-QuIC was shown in patients with longer disease duration and more advanced disease stage and correlated with the presence of REM sleep behavior disorder, cognitive impairment, and constipation. The α-synuclein RT-QuIC assay of minimally invasive skin punch biopsy is a reliable and reproducible biomarker for Parkinson’s disease. Moreover, α-synuclein RT-QuIC seeding activity in the skin may serve as a potential indicator of progression as it correlates with the disease stage and certain non-motor symptoms.


1981 ◽  
Vol 92 (5) ◽  
pp. 737
Author(s):  
Joseph W. Sassani ◽  
Jonathan Cutler
Keyword(s):  

2020 ◽  
Vol 9 (2) ◽  
pp. 95
Author(s):  
Rina Funada ◽  
Kazushige Adachi ◽  
Yoshimitsu Yamamoto ◽  
Itsuko Nakamichi

Micromachines ◽  
2020 ◽  
Vol 11 (1) ◽  
pp. 98 ◽  
Author(s):  
Manh Hoang ◽  
Viet Le ◽  
Kim Nguyen ◽  
Van Nguyen ◽  
Jayoung Kim ◽  
...  

Capsule endoscopes (CEs) have emerged as an advanced diagnostic technology for gastrointestinal diseases in recent decades. However, with regard to robotic motions, they require active movability and multi-functionalities for extensive, untethered, and precise clinical utilization. Herein, we present a novel wireless biopsy CE employing active five degree-of-freedom locomotion and a biopsy needle punching mechanism for the histological analysis of the intestinal tract. A medical biopsy punch is attached to a screw mechanism, which can be magnetically actuated to extrude and retract the biopsy tool, for tissue extraction. The external magnetic field from an electromagnetic actuation (EMA) system is utilized to actuate the screw mechanism and harvest biopsy tissue; therefore, the proposed system consumes no onboard energy of the CE. This design enables observation of the biopsy process through the capsule’s camera. A prototype with a diameter of 12 mm and length of 30 mm was fabricated with a medical biopsy punch having a diameter of 1.5 mm. Its performance was verified through numerical analysis, as well as in-vitro and ex-vivo experiments on porcine intestine. The CE could be moved to target lesions and obtain sufficient tissue samples for histological examination. The proposed biopsy CE mechanism utilizing punch biopsy and its wireless extraction–retraction technique can advance untethered intestinal endoscopic capsule technology at clinical sites.


2010 ◽  
Vol 80 (5) ◽  
pp. 383-383 ◽  
Author(s):  
Thomas Sjøberg ◽  
Louis De Weerd

Author(s):  
Melinda H. MacDonald ◽  
Gary Zhang ◽  
Laura Tasse ◽  
Daidong Wang ◽  
Hector De Leon ◽  
...  

AbstractTopical hemostatic agents have become essential tools to aid in preventing excessive bleeding in surgical or emergency settings and to mitigate the associated risks of serious complications. In the present study, we compared the hemostatic efficacy of SURGIFLO® Hemostatic Matrix Kit with Thrombin (Surgiflo—flowable gelatin matrix plus human thrombin) to HEMOBLAST™ Bellows Hemostatic Agent (Hemoblast—a combination product consisting of collagen, chondroitin sulfate, and human thrombin). Surgiflo and Hemoblast were randomly tested in experimentally induced bleeding lesions on the spleens of four pigs. Primary endpoints included hemostatic efficacy measured by absolute time to hemostasis (TTH) within 5 min. Secondary endpoints included the number of product applications and the percent of product needed from each device to achieve hemostasis. Surgiflo demonstrated significantly higher hemostatic efficacy and lower TTH (p < 0.01) than Hemoblast. Surgiflo-treated lesion sites achieved hemostasis in 77.4% of cases following a single product application vs. 3.3% of Hemoblast-treated sites. On average, Surgiflo-treated sites required 63% less product applications than Hemoblast-treated sites (1.26 ± 0.0.51 vs. 3.37 ± 1.16). Surgiflo provided more effective and faster hemostasis than Hemoblast. Since both products contain thrombin to activate endogenous fibrinogen and accelerate clot formation, the superior hemostatic efficacy of Surgiflo in the porcine spleen punch biopsy model seems to be due to Surgiflo’s property as a malleable barrier able to adjust to defect topography and to provide an environment for platelets to adhere and aggregate. Surgiflo combines a flowable gelatin matrix and a delivery system well-suited for precise application to bleeding sites where other methods of hemostasis may be impractical or ineffective.


Sign in / Sign up

Export Citation Format

Share Document